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ABSTRACT
Background Adherence to antidepressant therapy
remains a major issue worldwide. Most people with
depression are treated in a general practice setting,
but many stop taking antidepressants before com-
pleting a six-month course as recommended by
guidelines.
Objectives To determine antidepressant adher-
ence rates as indicated in primary care prescribing
data and pharmacy dispensing data; to demonstrate
commonly occurring patterns related to non-ad-
herence, using a prescription visualisation tool we
have developed; and to determine whether pre-
scribing data is a good predictor of dispensing based
adherence.
Methods We analysed general practice electronic
prescribing data for the year ending 31 December
2006 and linked pharmacy dispensing records by
National Health Index. We calculated medication
adherence for patients starting antidepressants using a
six-month evaluation period and a gap-based ad-
herence measure. Patients with a gap of more than
15 days in antidepressant therapy were considered
non-adherent. Using a prescription visualisation
tool, we described commonmodes of non-adherence.
Results Out of 2713 patients, 153 satisﬁed our
inclusion criteria. Thirty-nine percent of patients
showed poor adherence based on prescribing and
68% showed poor adherence on dispensing. Pre-
scribing based non-adherence had a positive predic-
tive value of 98% (95% CI 92%–99%) and negative
predictive value of 51% (CI 47%–52%) for dispens-
ing based non-adherence. Three broad categories of
non-adherence were identiﬁed: 1) failure to return
for re-prescription, 2) failure to maintain adher-
ence despite initial attempts and 3) failure to return
for re-prescription in a timely manner.
Conclusions Prescribing data identiﬁes substan-
tial adherence issues in antidepressant therapy.
Clinicians should consider adherence issues as part
of the overall treatment regime and discuss such
issues during consultations.
Keywords: ambulatory care information systems,
clinical audit, patient non-adherence, quality indi-
cators
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Introduction
Depression is among the most treatable of mental
disorders – between 80 and 90% of people eventually
respond well to treatment and return to their normal
lives,1 yet a major issue in the management of de-
pression is poor adherence to antidepressant therapy.2
Treatment guidelines provide guidance on optimal
choice ofmedicine3 and guidelines such as the ones by
the National Institute for Health and Clinical Excellence
in the UK4 and the New Zealand (NZ) Guidelines
Group5 suggest a minimum of six months of continu-
ous antidepressant therapy for the ﬁrst episode of
depression and longer for subsequent episodes. How-
ever, research indicates that 44% of patients stop
taking medication by the third month of therapy.6
Although not all patients can be expected to beneﬁt,
high rates of adherence to evidence-based treatment
can be expected to deliver the best health outcomes for
a population with the given condition.
Most people with depression are treated in a general
practice setting, either by a general practitioner (GP)
alone or, for more serious depression, in partnership
with specialist mental health services.7 Therefore, we
work on the premise that routinely collected prescrib-
ing data stored in the electronicmedical record (EMR)
in a general practice setting can be used to detect
patients who show poor adherence to antidepressant
therapy (and hence on suboptimal therapy). Nearly
100% of GPs in NZ use an EMR. In a survey of GP
EMRs in 11 countries, NZ had the highest rate of
provision of 14 desirable computer functions.8 This
presents an excellent foundation for use of EMR data
to support quality improvement eﬀorts, and in par-
ticular to actively identify and manage non-adherent
patients. In this paper we attempt to combine high
quality EMR data with a novel visualisation tool that
can be used to enhance GP–patient communication
on adherence issues and assist GPs and patients to be
more aware of non-adherence.
Most antidepressant adherence related studies in
the past have been carried out using pharmacy dis-
pensing claims data,2,9–11 and therefore we also inves-
tigate adherence rates as indicated in dispensing
records. In NZ, the government pays a substantial
amount of the overall pharmaceutical expenses (this
was 67% in 2008,12 but has been considerably more
since September 2008 when patient co-payments were
dropped to NZ $3 or less for all patients) as determined
by a Pharmaceutical Schedule set by the Pharmaceutical
Management Agency (PHARMAC). Community phar-
macies submit electronic claims for reimbursement of
the government funded components of dispensed
medicines to a centralised reimbursement system.
Almost all NZ pharmacies use computers as part
of their business.13 NZ also beneﬁts from a National
Health Index (NHI) – a unique patient identiﬁer
which provides an opportunity to uniquely match a
general practice’s prescribing data to pharmacy
dispensing data from across the country.
In this paper, we focus on the use of prescribing
EMR data to identify patients on suboptimal therapy
using a gap-based adherence measure. We then dis-
cuss several patterns of non-adherence that we have
observed in our dataset. We also analyse community
pharmacy dispensing records to determine how anti-
depressant prescription data compares to pharmacy
claims data.
Methods
We examine adherence rates of antidepressant medi-
cines, each of which is listed on the Pharmaceutical
Schedule and is therefore fully or partly funded by
government. The medications that were considered
were among the 20 diﬀerent antidepressant medicines
recognised by the NZ Ministry of Health.14
Adherence to medication
Adherence refers to the extent to which a patient
follows the medical instructions and recommendations
from the prescriber.15 In this paper we employ a gap-
based adherencemeasure which is an indication of the
time of continuous therapy. For our purposes, we
allow a ‘permissible gap’ of 15 days, which is the
maximum allowable period patients could go without
a dose and not anticipate reduced or suboptimal
outcomes;16 patients who have gaps (also referred to
as ‘lapses’) in treatment exceeding this duration are
deemed non-adherent.
Our adherence computation is based on whether
the patient was covered by any antidepressant medi-
cation on a given day within the evaluation period
(EP), with no consideration of stockpiling of supply
between prescriptions. Although somewhat rare, we
have seen cases where, for example, amitriptyline and
paroxetine or doxepin and ﬂuoxetine have been
prescribed as concurrent medications. Simple add-
ition of durations may be accurate for patients on
monotherapy, however, in the former example, if
amitriptyline and paroxetine were both prescribed
for 90 days, 120 days prior to the end of our EP, our
analysis would show that a patient had a 30-day gap
towards the end of the EP. Therefore our adherence
computation scheme can handle not only patients on
monotherapy, but also cases where patients are on
multiple agent therapy, which is often the case with
complex patients. This has been acknowledged by
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other researchers and often only patients on mono-
therapy are considered in order to ‘reduce the com-
plexity in measuring medication adherence’17 and
patients on concurrent therapy are excluded due to
the fact that it is diﬃcult ‘to deﬁne adherence formore
than one medication concurrently’.9 We have pre-
viously shown that taking such factors into consider-
ation provides a more eﬀective measure of adherence.18
Analysis protocol
Unlike a chronic condition such as diabetes, many
patients with depression can be successfully with-
drawn from treatment after an initial treatment period
and therefore do not need to be on antidepressants for
the rest of their lives. We used a six-month period,
from 1 July 2006 to 31 December 2006, as our EP.
We included only patients who had had an anti-
depressant-free period of six months prior to the start
of our EP, i.e. no antidepressant prescription during
the period from 1 January 2006 to 30 June 2006. Using
this protocol, we examine the prescribing of anti-
depressant medicines and their community pharmacy
dispensing. Only funded patients enrolled at the
practices were included (all New Zealand citizens and
permanent residents can be enrolled with one primary
healthcare organisation (PHO), which is funded for
the management of that person; each general practice
is associated with a PHO). The analysis included the
following steps:
1 separation of the cases with a therapy gap exceeding
the 15-day threshold based on prescribing data into
the ‘adherent’ and ‘non-adherent’ groups
2 visual inspection of the patterns of treatment and
lapse in the non-adherent group
3 comparison of adherence status with prescribing to
that based on dispensing, including computation
of the positive predictive value (PPV) and negative
predictive value (NPV) of non-adherence with
prescribing for non-adherence on dispensing
4 computation of a logistic regression model of dis-
pensing adherence based on demographic factors
(using the Microsoft Excel 2010 Data Analysis
tools) with andwithout the inclusion of prescribing
adherence as a factor.
Data extraction
We collaborated with a multi-physician NZ general
medical practice from metropolitan Auckland. Pre-
scribing data, patient gender, age, ethnicity and socio-
economic coding were extracted from this practice’s
proprietary EMR (MedTech32 –www.medtechglobal.
com/ (accessed 29 June 2011) ) into a password-
protected research database, retaining NHI but re-
moving other identifying information including name
and address. The pharmacy dispensing records for
government subsidised medicines for these patients
were extracted from the national claims database, as
matched on NHI, by the NZ Health Information
Service (now part of the Information Directorate) of
the Ministry of Health, and then merged into the
research database. Data were analysed by non-pro-
prietary, generic, active ingredient in order to account
for brand and generic substitution.
The EMR data extracted from the practice manage-
ment system (PMS) contained prescribing records
for the 12-month period from 1 January 2006 to
31December 2006. Patient ethnicity data (i.e. whether
a patient identiﬁed himself or herself asMaori, Paciﬁc,
European or Asian) as well as socio-economic quintile
data (based on census data and patient address) were
also extracted for these patients. The data extract
involved 2713 enrolled and funded patients and
21 868 prescriptions (around 4.2% of these for anti-
depressants). The pharmacy dataset included dispensing
data for the 15-month period from 1 January 2006 to
31 March 2007 for these 2713 patients, linked by their
NHI. In NZ, a prescription (with reﬁlls) is valid for a
period of three months before it expires (medication
may be dispensed as three months supply at once, or a
one-month supply at a time may be collected from a
single three-month prescription); hence the pharmacy
dispensing data was extracted for an additional three
months beyond the date of the last prescription. The
dispensing dataset included data for 2452 of the 2713
patients identiﬁed in the prescribing dataset and
49 716 dispensing records (around 5% of these for
antidepressants). This data extraction and analysis
process was approved under the Northern Regional
Ethics Committee protocol number NTX/07/55/EXP.
Results
Medication lapses in antidepressant
therapy
We ﬁrst analysed prescribing data to identify adher-
ence issues in antidepressant therapy, as indicated
in the practice’s EMR. One hundred and ﬁfty-three
patients satisﬁed our inclusion criteria and were
therefore inferred to have started their antidepressant
therapy during the EP. Out of these patients, 59 were
identiﬁed as being non-adherent.
Using the prescription visualisation tool we devel-
oped as part of the ChronoMedIt framework,19 we
then visually inspected the various antidepressant
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prescribing patterns for the non-adherent patients
(Figure 1).
The top timeline in Figure 1 shows a case where
there was only a single 90-day prescription. The second
case is consistent with the GP deciding to start the
patient on a short, 30-day course (perhaps to check
on eﬃcacy and whether the patient had any adverse
reactions) and then prescribing a normal 90-day script
when the patient returned for the next prescription.
However, this patient has not had a full six months of
antidepressant therapy, hence the guideline has not
been complied with. The last case is a typical scenario
where the patient appears to have failed to return on
time for the second prescription, possibly as a result of
using medication intermittently such that the supply
lasted longer than it would have if taken regularly.
These three cases represent three broad categories
of non-adherence, which we respectively identify as
1) failure to return for re-prescription, 2) failure to
maintain adherence despite initial attempts (note that
there is only a single re-prescription for 90-days with
respect to the second case in Figure 1, but this could
have even been three 30-day re-prescriptions, still
having the same aﬀect) and 3) failure to return for
re-prescription in a timely manner. Through visual
inspection of the individual cases, all other cases of
non-adherence were concluded to be a variation or a
combination of these three categories.
Figure 2 shows several cases related to adherent
patients. The ﬁrst case satisﬁes the minimum
guideline requirements while the other two patients
have been on antidepressants for a longer duration.
The second patient in Figure 2 and the second patient
in Figure 1 have some similarity as the patient was
started on a shorter 30-day duration script and then
moved onto a standard 90-day script, and it is possible
that the prescribing pattern seen in the second patient
in Figure 2 was the GP’s intention for the second
patient in Figure 1 as well.
Prescribing vs dispensing based
adherence
The results of matching the patients satisfying our
inclusion criteria to their dispensing via NHIs are
shown in Table 1.
We constructed a logistic regression model of
dispensing based non-adherence to determine what
factors were associated with adherence to anti-
depressant dispensing for our cohort of 153 patients.
Out of these, 21 patients had only prescribing records
Figure 1 Commonly occurring patterns related to non-adherence. The tooltip in the top ﬁgure shows further
details related to the selected prescription
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(i.e. no dispensing), and a lapse of more than 15 days
in dispensing was ascribed to them. Characteristics of
the included patients are shown in Table 2.
The dependent variable for regression was a binary
indicator for lapsed versus not lapsed based on dis-
pensing data. Independent variables, shown in Table 2,
were: age categories; gender; ethnicity (treated as a
series of binary indicators with European omitted as
the reference); and being in themost depressive socio-
economic quintile. None of the independent variables
were statistically signiﬁcant in the model.
We then extended ourmodel by including prescrib-
ing based adherence (zero/one for presence of a lapse
ofmore than 15 days) for each patient. This model has
an adjusted R-squared of 0.2143. The one signiﬁcant
variable is the prescribing adherence (P <0.001; coef-
ﬁcient=0.44, 95% CI 0.31–0.58).
Discussion
This study analysed antidepressant non-adherence
using general practice prescribing data and pharmacy
dispensing data. Prescription-based non-adherence
was observed to provide 98% PPV and 51% NPV for
dispensing based non-adherence. Thus, an adherence
problem revealed in prescribing appears worthy of
action (note in Table 1 that only one person out of 153
was adherent in dispensing despite being non-adher-
ent in prescribing). While the PPV is very good, it is
notable that prescribing only detects about half of the
potential problems as compared to dispensing data
(and of course both prescribing and dispensing are
only surrogates for knowledge of whether the patient
actually took the medication). Moreover, a regression
model of adherence found no simple demographic
Figure 2 Several prescribing patterns for adherent patients
Table 1 Association of prescribing based non-adherence and dispensing based non-
adherence (n=153)
Prescribing Dispensing PPV NPV
>15-day lapse No lapse (95% CI) (95% CI)
>15-day lapse 58 (38%) 1 (1%) 0.98 0.51
No lapse 46 (30%) 48 (31%) (0.92–0.99) (0.47–0.52)
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predictors (from age, gender, ethnicity or socio-econ-
omic status) that could substitute for prescribing data.
Our results also indicate, as expected, that anti-
depressant adherence problems in the community are
very commonplace, irrespective of whether prescrib-
ing or dispensing data are used as the indicator. Our
results indicate that poor adherence rates were 39%
and 68% based respectively on prescribing and dis-
pensing.The increase in non-adherence fromdispensing
as compared to prescribing is unsurprising; for example,
Bailey et al20 report that reﬁll failure occurred in 33%
of reﬁll opportunities. Moreover, our non-adherence
rates are consistent with the high rates of non-adherence
other researchers have reported. Using a ten-day grace
period for maximum lapse duration allowed, Bambauer
et al9 reported that around 75%of the patients showed
poor adherence in dispensing data. Cantrell et al2
reported that approximately 57% of patients were
non-adherent to antidepressant therapy using a six-
month EP, while Doesschate et al21 reported anti-
depressant non-adherence rates ranging from 39.7%
to 52.7%, with a mean of 46.5% over two years.
A main goal of this study is to inform GPs so that
they become more aware of antidepressant non-ad-
herence in the community and to demonstrate a few
commonly occurring types of prescribing patterns.
Our intention is not to criticise any (in)action by the
collaborating practice, but to make clinicians (and
health information technology innovators) more aware
of the existing high prevalence of non-adherence, and
its detectability from electronic prescribing and dis-
pensing records. This provides a fertile ground for
useful interventions, either in the form of interactive
decision support alerts during the doctor–patient
encounter, or more proactively through study of
population patterns to devise targeted adherence
promotion strategies.
Within the scope of this study, we identiﬁed three
broad patterns related to non-adherence: 1) failure
to return for re-prescription, 2) failure to maintain
adherence despite initial attempts and 3) failure to
return for re-prescription in a timely manner. Each of
these would probably be amenable to a distinct ad-
herence promotion strategy and serves to inform a
further development of a model of medication adher-
ence. We also demonstrated the use of a prescription
visualisation tool to support clinicians in seeing the
nature of adherence problems as indicated in the data
(which may be diﬃcult to discern in a tabular list of
prescribing dates). Such a visual representation could
act as a prompt and a facilitator of discussion with
patients to determine factors that may have con-
tributed to the non-adherence pattern and/or regard-
ing how long to continue medication.
If previous dispensing data is readily available at the
point of prescribing, clinicians can have even more
informed conversations with patients (i.e. regarding
their reﬁll adherence) as compared to when using
prescribing data alone. This use of dispensing data could
entail ethical implications with respect to the patient’s
Table 2 Characteristics of patients prescribed antidepressant medication (n=153)
Characteristic Number of patients (%) Number of non-adherent patients
(as a % of non-adherent patients,
n=59)
Age (years)
<30 23 (15%) 9 (15%)
30–44 36 (24%) 12 (20%)
45–59 45 (29%) 20 (34%)
60–74 31 (20%) 11 (19%)
75+ 18 (12%) 7 (12%)
Gender
Female 111 (73%) 40 (68%)
Male 42 (27%) 19 (32%)
Ethnicity
Maori 8 (5%) 4 (7%)
Paciﬁc 2 (1%) 0 (0%)
European 138 (90%) 53 (90%)
Asian 1 (1%) 0 (0%)
Other 4 (3%) 2 (3%)
Most deprived quintile 30 (20%) 13 (22%)
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privacy which would need to be resolved in advance of
the use of such a network. Conversely, we see no issue
in the use of practice-based prescribing data since this
only involves the GPs of a practice exercising aware-
ness of the records of their own actions.
Although depression is recognised as one of the
most treatable of mental disorders and adherence to
treatment identiﬁed as a key factor in recovery, the
diagnosis and management of depression is not with-
out contention and complexity.22 Primary care phys-
icians manage a wide range of human experience and
suﬀering including grief, adjustment, personality dis-
orders, substance abuse, medical illness, pain and
sleep disorders that can merge in a less than discrete
way with the concept of depression. Both the clinician
and patient may have diﬀerent understandings and
levels of conviction as to the appropriate diagnosis and
most available and optimal treatment, but agree that
depression is a valid working model to describe the
patient’s experience and that it is appropriate to trial
an antidepressant. Exclusively categorising depression
is not deﬁnitive (e.g. the NZ depression guidelines5
refer to severe, moderate and mild depression –
medication is considered compulsory for severe, a
good option for moderate and not initially indicated
for mild depression); in practice there are often
important triggering or exacerbating factors such as
relationship or work diﬃculties that vary over time.
The natural history of depression is that it often
resolves over time (and, on the other hand, that it
also recurs), and that it is common for patients to
come for help when they have been depressed for a
long time and may therefore be approaching natural
recovery. Moreover, it is common for patients to stop
medication because they feel themselves to be recov-
ering, or not recovering despite medication. Also,
culture, context, prior experience, personal and family
biases and preferences, trust and therapeutic alliance,
memory, judgement and motivation, level of side
eﬀects and patient response are all factors that may
impact on ongoing adherence. Tools and techniques
such as the ones discussed herein are promising to
provide support, but the complexity of the task must
be kept in mind.
Low adherence is a complex issue without a single
solution, however, low adherence is an indication of
the need for improved communication between GPs
and patients; possibly the clinician needs to engage the
patient more in a joint ‘problem-solving’ approach
in relation to underlying adherence barriers and
use novel tools (e.g. the visualisation tool discussed
herein) to explain optimal prescribing patterns to
patients. This is an important issue as there is evidence
to suggest that providers often do not ask about
medication adherence from patients, and may not
use the most eﬀective communication strategies when
they do.23 Research has shown that patients prefer
graphical representations the most (compared to
numerical values such as number needed to treat)
when encouraging patients to take medication, and
that consideration should be given to developing visual
aids to support shared clinical decision making.24
Educating and discussing issues is also supported by
a recent study in NZ where the researchers inves-
tigated patient beliefs about medication and found
that ‘patient concerns with medications were posi-
tively associated with (self-reported) non-adherence’.25
Other investigators also have demonstrated that ‘inter-
personal process variables (such as greater levels
of patient–provider collaboration) are important in
inﬂuencing antidepressant adherence’.26
Studies to date thatmatch prescribing to dispensing
in an open-loop healthcare system (i.e. where pre-
scribing and dispensing do not operate from a single
central database) have been limited.We havematched
prescribing data to dispensing data based on the NHI
number, providing a simple and robust means of
matching patients between general practice and com-
munity pharmacy. Previous research investigated
success rates of linking prescribing records to dispens-
ing records (using probabilistic matching techniques)
based on a combination of patient characteristics,
such as gender, year of birth and postal code, and
prescription characteristics, including prescription date
and Anatomical Therapeutic Chemical-codes; this
resulted in a smaller dispensing-to-prescribing data
linkageproportionof64.8%.27Webelieveourmatching,
based on the NHI number, provides a more accurate
indication of the value of prescribing data to indicate
adherence in dispensing.
Good adherence has been associated with lower
yearly medical costs,2 less likelihood of experiencing
short-term disability events,28 lower risk of hospital-
isation and emergency room visits11 and fewer recur-
rent episodes of depression.29 Our work presents an
opportunity for practices to enhance the capacity for
having better conversations with patients. A possible
intervention can be designed for identiﬁed patients to
educate them on the importance of medication ad-
herence. GPs can use a tool such as the one presented
herein to discuss adherence issues with patients, and
perhaps even print a copy of the individual patient
graphs at the end of each encounter to make patients
more aware of individual adherence. We have dis-
cussed how analysing prescribing data is a reasonably
good measure of dispensing adherence and can be
used to identify patients with good/bad adherence,
and intuitively the absence of timely prescription in
the general practice EMR should be a strong indicator
of an underlying problem in medication supply and
adherence and could ultimately lead to better clinical
outcomes.
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We acknowledge several limitations in our investi-
gation:
1 Our study was based on a relatively small sample of
patients from a single general practice. Extracting
data from several general practices or a large PHO
that manages several general practices would pro-
vide a more robust assessment.
2 Our data was based on general practice prescribing
data and it is possible that not all prescriptions were
issued by the general medical practice from which
we extracted the EMR data. It is possible that some
prescriptions were issued during a patient’s stay in
hospital, or from the community specialist mental
health service, in which case the record would appear
in the dispensing data but not in the prescribing
data – in fact, there were 195 patients identiﬁed in
our dispensing dataset as being eligible and satis-
fying our inclusion criteria, however, only 153 had
prescriptions issued by the collaborating practice.
Further, some medication may have been stopped
by the GP (perhaps after three months), but such
information is not recorded in the EMR, and
therefore is not accounted for in our analysis.
3 Clinical assessments such as the Patient Health
Questionnaire-9 (PHQ-9)30 can be used to moni-
tor response to treatment and if such information is
made available within an EMR system, outcomes of
identiﬁed patients can be closely correlated to
medication adherence. However, PHQ-9 data is
not available within the PMS at the moment and
therefore this study has not investigated any direct
patient outcomes.
Conclusions
Patient adherence to antidepressant treatment is poor.
There is evidence to suggest that substantial adherence
issues can be identiﬁed by analysing prescribing data,
and therefore clinicians need to consider poor adher-
ence to antidepressant therapy as common and should
at least discuss such issues with patients during con-
sultations. Linking dispensing data to corresponding
prescribing records conﬁrms that there is merit in
analysing a patient’s prescribing record; such analysis
at the point of prescribing should be promoted, possibly
including the support of graphic tools. Further work is
needed to determine what type of clinical interventions
would be best suited to improving patient adherence
to antidepressant therapy.
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